Evaluating the case for trivalent or quadrivalent influenza vaccines

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 10, 2016, Pages 2712-2717

  Baxter, David ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Trivalent Quadrivalent Influenza vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SIALIDASE;

COUNTRY ECONOMIC STATUS; DISEASE SURVEILLANCE; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MORTALITY RATE; NONHUMAN; REVIEW; VACCINATION; VIRUS TRANSMISSION; IMMUNOLOGY; INFLUENZA, HUMAN; VIROLOGY;

HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84978655519     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1091130     Document Type: Review

References (44)

1. S.A.Plotkin, E.A.Mortimer. Vaccines:W B Saunders Company; 1988
2. J.M.Wilschut, J.E.McElhaney, J.E.Palachie, AM. Influenza. Second ed:Mosby, Elsevier; 2006
3. Viral Infections of Humans - Epidemiology and Control. Third ed. New York and London:Plenum Medical; 1991
4. N.M.Bouvier, P.Palese. The biology of influenza viruses. Vaccine 2008 9/12/; 26, Supplement 4(0):D49-53; PMID:19230160; http://dx.doi.org/10.1016/j.vaccine.2008.07.039
5. V.Peltola, T.Ziegler, O.Ruuskanen. Influenza A and B virus infections in children. Clinical infectious diseases:an official publication of the Infectious Diseases Society of America. 2003; 36(3):299-305; PMID:12539071
6. J.G.Newland, J.R.Romero, M.Varman, C.Drake, A.Holst, T.Safranek, K.Subbarao. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. Clin Infect Dis 2003; 36(7):e87-95; PMID:12652406; http://dx.doi.org/10.1086/368184
7. S.Oropesa, P.Lago, A.Goyenechea, B.Hernández, M.Bello, R.L.Palomera Z.Morier L.P.GonzalezL Perez. Rapid death in children by type B influenza virus associated with neurological complications. Int Congress Series 2004; 1263(0):350-4; http://dx.doi.org/10.1016/j.ics.2004.04.005
8. C.S.Ambrose, M.J.Levin. The rationale for quadrivalent influenza vaccines. Human Vaccines & Immunotherapeutics. 2012; 8(1):81-8; PMID:22252006
9. S.Katagiri, A.Ohizumi, M.Homma. An outbreak of type C influenza in a children's home. J Infect Dis 1983; 148(1):51-6; PMID:6309999; http://dx.doi.org/10.1093/infdis/148.1.51
10. GAR. Global Alert and Response - WHO Global Influenza Surveillance Network [cited 2015 05/05/2015]. Available from:http://apps.who.int/csr/disease/influenza/surveillance/en/index.html
11. FluNet. Influenza:WHO; 2015 [cited 2015 05/05/2015]. Available from:http://www.who.int/influenza/gisrs_laboratory/flunet/en/
12. GISN. Global Influenza Surveillance Network - Influenza Update 2014 [cited 2014 01/05/2015]. Available from:http://www.who.int/influenza/surveillance_monitoring/updates/2014_12_01_update_GIP_surveillance/en/
13. WHO. Influenza (Seasonal) 2014 [cited 2015 15/05/2015]. Available from:http://www.who.int/mediacentre/factsheets/fs211/en/
14. F.S.Dawood, A.D.Iuliano, C.Reed, M.I.Meltzer, D.K.Shay, P.Y.Cheng, D.Bandaranayake, R.F.Breiman, W.A.Brooks, P.Buchy, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation:a modelling study. Lancet Infect Dis 2012; 12(9):687-95; PMID:22738893; http://dx.doi.org/10.1016/S1473-3099(12)70121-4
15. E.E.Waffarn, N.Baumgarth. Protective B Cell Responses to Flu—No Fluke! J Immunol 2011; 186(7):3823-9; PMID:21422252; http://dx.doi.org/10.4049/jimmunol.1002090
16. P.A.Rota, T.R.Wallis, M.W.Harmon, J.S.Rota, A.P.Kendal, K.Nerome. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175(1):59-68; PMID:2309452; http://dx.doi.org/10.1016/0042-6822(90)90186-U
17. F.Dijkstra, G.A.Donker, B.Wilbrink, A.B.Van Gageldonk-Lafeber, M.A.Van Der Sande. Long time trends in influenza-like illness and associated determinants in The Netherlands. Epidemiol Infect 2009; 137(4):473-9; PMID:18789176; http://dx.doi.org/10.1017/;S095026880800126X
18. M.L.Yang, Y.H.Chen, S.W.Wang, Y.J.Huang, C.H.Leu, N.C.Yeh, C.Y.Chu, C.C.Lin, G.S.Shieh, Y.L.Chen, et al. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. J Virol 2011; 85(19):10010-20; PMID:21795357; http://dx.doi.org/10.1128/;JVI.00301-11
19. J.E.Stencel-Baerenwald, K.Reiss, D.M.Reiter, T.Stehle, T.S.Dermody. The sweet spot:defining virus-sialic acid interactions. Nat Rev Microbiol 2014; 12(11):739-49; PMID:25263223; http://dx.doi.org/10.1038/nrmicro3346
20. I.Julkunen, T.Sareneva, J.Pirhonen, T.Ronni, K.Melén, S.Matikainen. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev 2001; 12(2-3):171-80; PMID:11325600; http://dx.doi.org/10.1016/S1359-6101(00)00026-5
21. D.M.Mitchell, A.J.McMichael, J.R.Lamb. The immunology of influenza. Br Med Bull 1985; 41(1):80-5; PMID:3882191
22. A.Iwasaki, P.S.Pillai. Innate immunity to influenza virus infection. Nat Rev Immunol 2014; 14(5):315-28; PMID:24762827; http://dx.doi.org/10.1038/nri3665
23. T.R.Cate, Y.Rayford, D.Niño, P.Winokur, R.Brady, R.Belshe, W.Chen, R.L.Atmar, R.B.Couch. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28(9):2076-9; PMID:20044052; http://dx.doi.org/10.1016/j.vaccine.2009.12.041
24. R.B.Couch, J.A.Kasel, J.L.Gerin, J.L.Schulman, E.D.Kilbourne. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129(4):411-20; PMID:4593871; http://dx.doi.org/10.1093/infdis/129.4.411
25. S.GlaxoSmithKline. Fluarix tetra - summary of product characteristics Electronic Medicines Compendium2015 [updated 24/03/2015]. Available from:http://www.medicines.org.uk/emc/medicine/27537
26. J.R.Davies, E.A.Grilli. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989; 102(2):325-33; PMID:2703026; http://dx.doi.org/10.1017/S0950268800030004
27. W.Künzel, H.Glathe, H.Engelmann, C.Van Hoecke. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14(12):1108-10; PMID:8911005; http://dx.doi.org/10.1016/0264-410X(96)00061-8
28. J.K.Breteler, J.S.Tam, M.Jit, J.C.Ket, M.R.De Boer. Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries:a systematic review and meta-analysis. Vaccine 2013; 31(45):5168-77; PMID:24012574; http://dx.doi.org/10.1016/j.vaccine.2013.08.056
29. M.T.Osterholm, N.S.Kelley, A.Sommer, E.A.Belongia. Efficacy and effectiveness of influenza vaccines:a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(1):36-44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
30. T.Jefferson, D.Rivetti, A.Rivetti, M.Rudin, C.Di Pietrantonj, V.Demicheli. Efficacy and effectiveness of influenza vaccines in elderly people:a systematic review. Lancet 2005; 366(9492):1165-74; PMID:16198765; http://dx.doi.org/10.1016/S0140-6736(05)67339-4
31. W.H.Barker, J.P.Mullooly. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244(22):2547-9; PMID:7431593; http://dx.doi.org/10.1001/jama.1980.03310220045026
32. T.Vu, S.Farish, M.Jenkins, H.Kelly. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20(13-14):1831-6; PMID:11906772; http://dx.doi.org/10.1016/S0264-410X(02)00041-5
33. H.J.Parish. A History of Immunization. Edinburgh and London:E and S Livingstone Ltd; 1965
34. M.M.Sigel, F.W.Shaffer, M.W.Kirber, A.B.Light, W.Henle. Influenza A in a vaccinated population. JAMA 1948; 136(7):437-41; PMID:22997639; http://dx.doi.org/10.1001/jama.1948.02890240003002
35. J.E.Salk. An interpretation of the significance of influenza virus variation for the development of an effective vaccine. Bull N Y Acad Med 1952; 28(11):748-65; PMID:12987937
36. J.B.Domachowske, H.Pankow-Culot, M.Bautista, Y.Feng, C.Claeys, M.Peeters, B.L.Innis, V.Jain. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207(12):1878-87; PMID:23470848; http://dx.doi.org/10.1093/infdis/jit091
37. D.P.Greenberg, C.A.Robertson, M.J.Noss, M.M.Blatter, R.Biedenbender, M.D.Decker. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31(5):770-6; PMID:23228813; http://dx.doi.org/10.1016/j.vaccine.2012.11.074
38. J.C.Tinoco, N.Pavia-Ruz, A.Cruz-Valdez, C.Aranza Doniz, V.Chandrasekaran, W.Dewé, A.Liu, B.L.Innis, V.K.Jain. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years:a phase III, randomized trial. Vaccine 2014; 32(13):1480-7; PMID:24486352; http://dx.doi.org/10.1016/j.vaccine.2014.01.022
39. J.Beran, M.Peeters, W.Dewé, J.Raupachová, L.Hobzová, J.M.Devaster. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine:a randomized, controlled trial in adults. BMC Infect Dis 2013; 13:224; PMID:23688546; http://dx.doi.org/10.1186/1471-2334-13-224
40. D.Kieninger, E.Sheldon, W.Y.Lin, C.J.Yu, J.M.Bayas, J.J.Gabor, M.Esen, J.L.Fernandez Roure, S.Narejos Perez, C.Alvarez Sanchez, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine:a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013; 13:343; PMID:23883186; http://dx.doi.org/10.1186/1471-2334-13-343
41. S.L.Block, T.Yi, E.Sheldon, F.Dubovsky, J.Falloon. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29(50):9391-7; PMID:21983154; http://dx.doi.org/10.1016/j.vaccine.2011.09.109
42. B.Y.Lee, S.M.Bartsch, A.M.Willig. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30(52):7443-6; PMID:23084849; http://dx.doi.org/10.1016/j.vaccine.2012.10.025
43. B.Y.Lee, S.M.Bartsch, A.M.Willig. Corrigendum to “The economic value of a quadrivalent versus trivalent influenza vaccine” [Vaccine 2012;30:7443-6]. Vaccine 2013; 31(20):2477-9; http://dx.doi.org/10.1016/j.vaccine.2013.04.013
44. L.A.Van Bellinghen, G.Meier, I.Van Vlaenderen. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK:a lifetime multi-cohort model. PLoS One 2014; 9(6):e98437; PMID:24905235; http://dx.doi.org/10.1371/journal.pone.0098437